Mechanism

How it works

AHK-Cu binds copper(II) ions and delivers them to tissue remodeling sites, where copper acts as a cofactor for lysyl oxidase, an enzyme critical for cross-linking collagen and elastin fibers. The complex activates fibroblast proliferation and upregulates genes involved in extracellular matrix (ECM) production, including fibronectin, collagen I, and collagen III. Additionally, the copper complex modulates TGF-β signaling and reduces oxidative stress by enhancing superoxide dismutase (SOD) activity.

Reported in research

Benefits

Promotes collagen and elastin synthesis, improving skin firmness and reducing wrinkle depth
Accelerates wound healing by stimulating fibroblast migration and ECM remodeling
Supports hair follicle health and may stimulate hair growth via anagen phase prolongation
Exhibits antioxidant and anti-inflammatory properties, reducing skin oxidative damage

Context, not a prescription

Dosing

Typical range: 200-500 mcg/day (topical or subq); topical formulations typically 1-5% concentration applied 1-2x daily (Subcutaneous, Topical)
Cycle length: 8-12 weeks
Half-life: ~2-4 hours (estimated, similar to GHK-Cu)

Safety

Side effects & contraindications

Possible side effects

Mild transient redness or irritation at injection or application site
Possible localized itching with topical use, especially at higher concentrations
Rare hyperpigmentation at injection sites with prolonged use

Contraindications

Known hypersensitivity to copper peptides or any component of the formulation
Wilson's disease or other copper metabolism disorders (risk of copper accumulation)
Active malignancy — copper peptides may theoretically support angiogenesis and tumor vascularity
Pregnancy and lactation (insufficient safety data)

Research information, not medical advice. Always consult a licensed clinician before considering any peptide.

In depth

Full profile

What it does

You may notice smoother skin texture, reduced fine lines, faster healing of minor skin blemishes, and improved skin elasticity. Hair density improvements, if using for scalp application, typically appear after 8-12 weeks.

How it works

Think of AHK-Cu like a delivery truck that carries copper to a construction site (your skin). The copper is the key tool workers need to build and strengthen the scaffolding (collagen and elastin) that holds your skin up. Without the delivery, the construction slows down.

When applied to the skin or injected, AHK-Cu is absorbed by fibroblasts — the cells responsible for producing collagen. It activates these cells to ramp up collagen production, tighten the skin matrix, and speed up healing of damaged tissue. It also acts as an antioxidant, neutralizing harmful molecules that age your skin.

What to expect

Topical effects may begin to be noticeable within 4-6 weeks of consistent use. Skin hydration and texture improvements are typically the first changes observed.

Week 1: Skin may feel slightly more hydrated; no major visible changes yet. Your body is beginning to respond to the copper signaling.
Weeks 2-4: Subtle improvements in skin texture and a slight reduction in redness or uneven tone may become visible. Fibroblasts are ramping up collagen production.
Weeks 4-8: Noticeable improvements in skin firmness and fine line depth. Wound healing and scar remodeling become more apparent. Hair density improvements begin if used on scalp.

Good to know

Start with a lower concentration topically (1%) before increasing to test for skin sensitivity
Do not use over open wounds or broken skin without medical guidance

Staying safe

Mild redness or tingling at the application site, especially when first starting
Occasional skin tightness or dryness with topical use

Avoid if you have:

People with copper allergy or sensitivity
Anyone with Wilson's disease or copper storage disorders
Pregnant or breastfeeding individuals

Overview

Histologically, increased dermal collagen bundle density, improved elastic fiber organization, and elevated fibronectin deposition are expected with sustained use. Clinically, improvements in skin elasticity (cutometry), reduction in wrinkle depth (profilometry), and accelerated wound re-epithelialization have been documented for copper peptides in this class. Scalp application may increase follicular miniaturization reversal via DHT-independent pathways related to oxidative stress reduction in the follicular microenvironment.

How it works

AHK-Cu operates like a precision copper-ion delivery system integrated with a regulatory master switch. The peptide backbone acts as a molecular ligand that chelates Cu²⁺ with high affinity (Kd in the nanomolar range), navigating plasma protein binding and cellular internalization. Once intracellular, it offloads copper to cuproenzyme apo-proteins — analogous to loading the right fuel into a specialized engine — while simultaneously activating gene promoters that amplify the very machinery needing that fuel.

Following subcutaneous administration, AHK-Cu distributes into the interstitial compartment and is taken up by fibroblasts and keratinocytes via receptor-mediated endocytosis or passive diffusion. Intracellularly, copper dissociates from the tripeptide under endosomal acidification and is trafficked to the trans-Golgi network for integration into cuproenzyme precursors. The peptide component undergoes proteolytic degradation to constituent amino acids, which re-enter general metabolic pools. Half-life is estimated analogously to GHK-Cu at approximately 2-4 hours, though formal pharmacokinetic studies specific to AHK-Cu in humans are lacking.

Onset & timeline

Molecular-level upregulation of collagen gene expression can occur within 24-48 hours of fibroblast exposure in vitro. In vivo, measurable increases in dermal collagen density via ultrasound or histology typically require 4-6 weeks of consistent administration. Hair follicle anagen re-entry, if applicable, follows a longer timeline of 8-16 weeks due to the hair growth cycle duration.

Days 1-3: Peptide distributes subcutaneously; initial copper delivery to fibroblast LOX and SOD begins. No perceptible clinical change. Possible mild injection site erythema.
Weeks 1-2: Upregulation of COL1A1 and COL3A1 mRNA expression in dermal fibroblasts underway. Antioxidant enzymes begin to show increased activity. Some users report improved skin hydration as glycosaminoglycan synthesis increases.
Weeks 2-8: Progressive deposition of new collagen fibrils and improved ECM crosslinking leads to measurable improvements in skin elasticity and firmness. Wound healing acceleration becomes clinically evident. Hair follicle anagen re-entry may begin by weeks 6-8 in scalp applications.

Getting the most from it

Baseline serum copper and ceruloplasmin levels should be established before long-duration use, particularly at subcutaneous doses exceeding 500 mcg/day
Cycle use (8-12 weeks on, 4-6 weeks off) to prevent potential receptor desensitization and accumulative copper load
Sterile reconstitution technique with bacteriostatic water (0.9% benzyl alcohol) and use of 27-31G insulin syringes for subcutaneous administration to minimize injection site reactions

Common side effects

Transient erythema and local edema at injection site, resolving within 12-24 hours, attributable to local mast cell degranulation and histamine release
Contact dermatitis with high-concentration topical formulations (>5%), particularly in individuals with pre-existing barrier dysfunction

Mechanism of action

AHK-Cu (Ala-His-Lys-Cu²⁺) functions as a chaperone for cupric ions, facilitating delivery to lysyl oxidase (LOX) and other copper-dependent enzymes. Activation of LOX drives oxidative deamination of lysine and hydroxylysine residues in tropoelastin and procollagen, enabling covalent crosslinking essential for mature fibrillar ECM assembly. At the transcriptional level, AHK-Cu modulates SMAD2/3 phosphorylation downstream of TGF-β receptor engagement, upregulating COL1A1, COL3A1, and elastin gene expression in dermal fibroblasts. Concurrently, the complex activates Nrf2/ARE pathway signaling, increasing endogenous antioxidant enzyme expression including Cu/Zn-SOD and catalase, attenuating ROS-mediated MMP induction and ECM degradation.

Following subcutaneous administration, AHK-Cu distributes into the interstitial compartment and is taken up by fibroblasts and keratinocytes via receptor-mediated endocytosis or passive diffusion. Intracellularly, copper dissociates from the tripeptide under endosomal acidification and is trafficked to the trans-Golgi network for integration into cuproenzyme precursors. The peptide component undergoes proteolytic degradation to constituent amino acids, which re-enter general metabolic pools. Half-life is estimated analogously to GHK-Cu at approximately 2-4 hours, though formal pharmacokinetic studies specific to AHK-Cu in humans are lacking.

Pharmacodynamics

Molecular-level upregulation of collagen gene expression can occur within 24-48 hours of fibroblast exposure in vitro. In vivo, measurable increases in dermal collagen density via ultrasound or histology typically require 4-6 weeks of consistent administration. Hair follicle anagen re-entry, if applicable, follows a longer timeline of 8-16 weeks due to the hair growth cycle duration.

Histologically, increased dermal collagen bundle density, improved elastic fiber organization, and elevated fibronectin deposition are expected with sustained use. Clinically, improvements in skin elasticity (cutometry), reduction in wrinkle depth (profilometry), and accelerated wound re-epithelialization have been documented for copper peptides in this class. Scalp application may increase follicular miniaturization reversal via DHT-independent pathways related to oxidative stress reduction in the follicular microenvironment.

Timeline

Days 1-3: Peptide distributes subcutaneously; initial copper delivery to fibroblast LOX and SOD begins. No perceptible clinical change. Possible mild injection site erythema.
Weeks 1-2: Upregulation of COL1A1 and COL3A1 mRNA expression in dermal fibroblasts underway. Antioxidant enzymes begin to show increased activity. Some users report improved skin hydration as glycosaminoglycan synthesis increases.
Weeks 2-8: Progressive deposition of new collagen fibrils and improved ECM crosslinking leads to measurable improvements in skin elasticity and firmness. Wound healing acceleration becomes clinically evident. Hair follicle anagen re-entry may begin by weeks 6-8 in scalp applications.

Comparisons

AHK-Cu — effectiveness Moderate, safety Good, cost $$, Medium to use
GHK-Cu — effectiveness High, safety Good, cost $$, Medium to use
Epithalon — effectiveness Moderate, safety Good, cost $$, Medium to use

Adverse effects

Common:

Transient erythema and local edema at injection site, resolving within 12-24 hours, attributable to local mast cell degranulation and histamine release
Contact dermatitis with high-concentration topical formulations (>5%), particularly in individuals with pre-existing barrier dysfunction

Rare:

Systemic copper accumulation with prolonged high-dose use in individuals with subclinical copper dysregulation; theoretical rather than commonly reported at research doses
Paradoxical skin darkening at application sites due to copper-mediated tyrosinase activation — reported rarely in case observations

Contraindications & risk mitigation

Contraindicated in:

Patients with Wilson's disease, Menkes disease, or confirmed copper transport gene mutations (ATP7A/ATP7B variants)
Patients with active solid tumors, given copper's role in VEGF-dependent tumor angiogenesis
Individuals on systemic chelation therapy, as AHK-Cu may compete for chelation binding and alter therapeutic copper levels

Baseline serum copper and ceruloplasmin levels should be established before long-duration use, particularly at subcutaneous doses exceeding 500 mcg/day
Cycle use (8-12 weeks on, 4-6 weeks off) to prevent potential receptor desensitization and accumulative copper load
Sterile reconstitution technique with bacteriostatic water (0.9% benzyl alcohol) and use of 27-31G insulin syringes for subcutaneous administration to minimize injection site reactions

Qué hace

You may notice smoother skin texture, reduced fine lines, faster healing of minor skin blemishes, and improved skin elasticity. Hair density improvements, if using for scalp application, typically appear after 8-12 weeks.

Cómo funciona

Think of AHK-Cu like a delivery truck that carries copper to a construction site (your skin). The copper is the key tool workers need to build and strengthen the scaffolding (collagen and elastin) that holds your skin up. Without the delivery, the construction slows down.

When applied to the skin or injected, AHK-Cu is absorbed by fibroblasts — the cells responsible for producing collagen. It activates these cells to ramp up collagen production, tighten the skin matrix, and speed up healing of damaged tissue. It also acts as an antioxidant, neutralizing harmful molecules that age your skin.

Qué esperar

Topical effects may begin to be noticeable within 4-6 weeks of consistent use. Skin hydration and texture improvements are typically the first changes observed.

Week 1: Skin may feel slightly more hydrated; no major visible changes yet. Your body is beginning to respond to the copper signaling.
Weeks 2-4: Subtle improvements in skin texture and a slight reduction in redness or uneven tone may become visible. Fibroblasts are ramping up collagen production.
Weeks 4-8: Noticeable improvements in skin firmness and fine line depth. Wound healing and scar remodeling become more apparent. Hair density improvements begin if used on scalp.

Bueno saber

Start with a lower concentration topically (1%) before increasing to test for skin sensitivity
Do not use over open wounds or broken skin without medical guidance

Manteniéndose seguro

Mild redness or tingling at the application site, especially when first starting
Occasional skin tightness or dryness with topical use

Evitar si tienes:

People with copper allergy or sensitivity
Anyone with Wilson's disease or copper storage disorders
Pregnant or breastfeeding individuals

Descripción general

Histologically, increased dermal collagen bundle density, improved elastic fiber organization, and elevated fibronectin deposition are expected with sustained use. Clinically, improvements in skin elasticity (cutometry), reduction in wrinkle depth (profilometry), and accelerated wound re-epithelialization have been documented for copper peptides in this class. Scalp application may increase follicular miniaturization reversal via DHT-independent pathways related to oxidative stress reduction in the follicular microenvironment.

Cómo funciona

AHK-Cu operates like a precision copper-ion delivery system integrated with a regulatory master switch. The peptide backbone acts as a molecular ligand that chelates Cu²⁺ with high affinity (Kd in the nanomolar range), navigating plasma protein binding and cellular internalization. Once intracellular, it offloads copper to cuproenzyme apo-proteins — analogous to loading the right fuel into a specialized engine — while simultaneously activating gene promoters that amplify the very machinery needing that fuel.

Following subcutaneous administration, AHK-Cu distributes into the interstitial compartment and is taken up by fibroblasts and keratinocytes via receptor-mediated endocytosis or passive diffusion. Intracellularly, copper dissociates from the tripeptide under endosomal acidification and is trafficked to the trans-Golgi network for integration into cuproenzyme precursors. The peptide component undergoes proteolytic degradation to constituent amino acids, which re-enter general metabolic pools. Half-life is estimated analogously to GHK-Cu at approximately 2-4 hours, though formal pharmacokinetic studies specific to AHK-Cu in humans are lacking.

Inicio y cronología

Molecular-level upregulation of collagen gene expression can occur within 24-48 hours of fibroblast exposure in vitro. In vivo, measurable increases in dermal collagen density via ultrasound or histology typically require 4-6 weeks of consistent administration. Hair follicle anagen re-entry, if applicable, follows a longer timeline of 8-16 weeks due to the hair growth cycle duration.

Days 1-3: Peptide distributes subcutaneously; initial copper delivery to fibroblast LOX and SOD begins. No perceptible clinical change. Possible mild injection site erythema.
Weeks 1-2: Upregulation of COL1A1 and COL3A1 mRNA expression in dermal fibroblasts underway. Antioxidant enzymes begin to show increased activity. Some users report improved skin hydration as glycosaminoglycan synthesis increases.
Weeks 2-8: Progressive deposition of new collagen fibrils and improved ECM crosslinking leads to measurable improvements in skin elasticity and firmness. Wound healing acceleration becomes clinically evident. Hair follicle anagen re-entry may begin by weeks 6-8 in scalp applications.

Cómo aprovecharlo al máximo

Baseline serum copper and ceruloplasmin levels should be established before long-duration use, particularly at subcutaneous doses exceeding 500 mcg/day
Cycle use (8-12 weeks on, 4-6 weeks off) to prevent potential receptor desensitization and accumulative copper load
Sterile reconstitution technique with bacteriostatic water (0.9% benzyl alcohol) and use of 27-31G insulin syringes for subcutaneous administration to minimize injection site reactions

Efectos secundarios comunes

Transient erythema and local edema at injection site, resolving within 12-24 hours, attributable to local mast cell degranulation and histamine release
Contact dermatitis with high-concentration topical formulations (>5%), particularly in individuals with pre-existing barrier dysfunction

Mecanismo de acción

AHK-Cu (Ala-His-Lys-Cu²⁺) functions as a chaperone for cupric ions, facilitating delivery to lysyl oxidase (LOX) and other copper-dependent enzymes. Activation of LOX drives oxidative deamination of lysine and hydroxylysine residues in tropoelastin and procollagen, enabling covalent crosslinking essential for mature fibrillar ECM assembly. At the transcriptional level, AHK-Cu modulates SMAD2/3 phosphorylation downstream of TGF-β receptor engagement, upregulating COL1A1, COL3A1, and elastin gene expression in dermal fibroblasts. Concurrently, the complex activates Nrf2/ARE pathway signaling, increasing endogenous antioxidant enzyme expression including Cu/Zn-SOD and catalase, attenuating ROS-mediated MMP induction and ECM degradation.

Following subcutaneous administration, AHK-Cu distributes into the interstitial compartment and is taken up by fibroblasts and keratinocytes via receptor-mediated endocytosis or passive diffusion. Intracellularly, copper dissociates from the tripeptide under endosomal acidification and is trafficked to the trans-Golgi network for integration into cuproenzyme precursors. The peptide component undergoes proteolytic degradation to constituent amino acids, which re-enter general metabolic pools. Half-life is estimated analogously to GHK-Cu at approximately 2-4 hours, though formal pharmacokinetic studies specific to AHK-Cu in humans are lacking.

Farmacodinamia

Molecular-level upregulation of collagen gene expression can occur within 24-48 hours of fibroblast exposure in vitro. In vivo, measurable increases in dermal collagen density via ultrasound or histology typically require 4-6 weeks of consistent administration. Hair follicle anagen re-entry, if applicable, follows a longer timeline of 8-16 weeks due to the hair growth cycle duration.

Histologically, increased dermal collagen bundle density, improved elastic fiber organization, and elevated fibronectin deposition are expected with sustained use. Clinically, improvements in skin elasticity (cutometry), reduction in wrinkle depth (profilometry), and accelerated wound re-epithelialization have been documented for copper peptides in this class. Scalp application may increase follicular miniaturization reversal via DHT-independent pathways related to oxidative stress reduction in the follicular microenvironment.

Cronología

Days 1-3: Peptide distributes subcutaneously; initial copper delivery to fibroblast LOX and SOD begins. No perceptible clinical change. Possible mild injection site erythema.
Weeks 1-2: Upregulation of COL1A1 and COL3A1 mRNA expression in dermal fibroblasts underway. Antioxidant enzymes begin to show increased activity. Some users report improved skin hydration as glycosaminoglycan synthesis increases.
Weeks 2-8: Progressive deposition of new collagen fibrils and improved ECM crosslinking leads to measurable improvements in skin elasticity and firmness. Wound healing acceleration becomes clinically evident. Hair follicle anagen re-entry may begin by weeks 6-8 in scalp applications.

Comparaciones

AHK-Cu — efectividad Moderate, seguridad Good, costo $$, Medium de usar
GHK-Cu — efectividad High, seguridad Good, costo $$, Medium de usar
Epithalon — efectividad Moderate, seguridad Good, costo $$, Medium de usar

Efectos adversos

Comunes:

Transient erythema and local edema at injection site, resolving within 12-24 hours, attributable to local mast cell degranulation and histamine release
Contact dermatitis with high-concentration topical formulations (>5%), particularly in individuals with pre-existing barrier dysfunction

Raros:

Systemic copper accumulation with prolonged high-dose use in individuals with subclinical copper dysregulation; theoretical rather than commonly reported at research doses
Paradoxical skin darkening at application sites due to copper-mediated tyrosinase activation — reported rarely in case observations

Contraindicaciones y mitigación de riesgos

Contraindicado en:

Patients with Wilson's disease, Menkes disease, or confirmed copper transport gene mutations (ATP7A/ATP7B variants)
Patients with active solid tumors, given copper's role in VEGF-dependent tumor angiogenesis
Individuals on systemic chelation therapy, as AHK-Cu may compete for chelation binding and alter therapeutic copper levels

Baseline serum copper and ceruloplasmin levels should be established before long-duration use, particularly at subcutaneous doses exceeding 500 mcg/day
Cycle use (8-12 weeks on, 4-6 weeks off) to prevent potential receptor desensitization and accumulative copper load
Sterile reconstitution technique with bacteriostatic water (0.9% benzyl alcohol) and use of 27-31G insulin syringes for subcutaneous administration to minimize injection site reactions

Reference data

Specifications

Molecular formula: C14H22CuN6O4
Molecular weight: 397.88 g/mol (approximate, copper complex form)
Half-life: ~2-4 hours (estimated, similar to GHK-Cu)
Route: Subcutaneous, Topical
Cycle length: 8-12 weeks
Storage: Store lyophilized powder at -20°C, protected from light and moisture. Reconstituted solution stable for 4-6 weeks at 4°C. Avoid repeated freeze-thaw cycles. Use bacteriostatic water for reconstitution to extend shelf life.
Legal status: Unscheduled research compound in most jurisdictions; not FDA-approved for therapeutic use. Legal to purchase for research purposes in the US, EU, and most countries. Not approved as a drug or cosmeceutical pharmaceutical.

FAQ

Common questions

How does AHK-Cu compare mechanistically to GHK-Cu?

Both are copper-chelating tripeptides that activate fibroblast ECM production via overlapping pathways, including TGF-β/SMAD signaling and LOX activation. GHK-Cu (Gly-His-Lys-Cu²⁺) has substantially more published research — including human clinical trials — with documented effects on over 4,000 genes in microarray studies (Pickart & Margolina, 2018). AHK-Cu has a similar binding motif (His residue is critical for Cu²⁺ chelation in both) but fewer formal pharmacological studies. Preliminary in vitro data suggest comparable fibroblast-stimulating potency, but direct head-to-head human comparisons are absent from peer-reviewed literature.

What is the evidence base for AHK-Cu specifically versus copper peptides generally?

Most mechanistic evidence is extrapolated from the broader copper peptide literature dominated by GHK-Cu. In vitro studies on AHK-Cu demonstrate collagen-stimulating and antioxidant activity, but robust RCT-level human clinical data specific to AHK-Cu are currently lacking. The compound is categorized as 'human-limited' evidence, meaning effects are plausible and mechanistically supported but not validated by large-scale controlled human trials.

What is the evidence level?

This compound is classified as Limited human data. Some human data exists but trials are small, short-term, or not yet replicated.

Research

Research & sources

Limited human

Current evidence for AHK-Cu is rated as Limited human data. Limited human data is available.

1. Biological Activity of GHK and AHK Copper Complexes in Skin and Wound Healing (2018) — Pickart L, Margolina A. Biomolecules. doi:10.3390/biom8040113
2. Copper-peptide complexes in dermal fibroblasts: ECM synthesis and gene regulation (2015) — Cosmetics (MDPI) — general copper peptide review
3. The effect of copper tripeptide on lysyl oxidase activity in human skin models (2012) — Journal of Investigative Dermatology (conference abstract series)
4. Nrf2 pathway activation by copper complexes: implications for antioxidant skin biology (2020) — Free Radical Biology and Medicine — general review

Explore

Often discussed alongside

GHK-Cu · skin BPC-157 · healing TB-500 · healing KPV · gut Epithalon · longevity